<SEC-DOCUMENT>0001193125-17-236064.txt : 20170726
<SEC-HEADER>0001193125-17-236064.hdr.sgml : 20170726
<ACCEPTANCE-DATETIME>20170726114334
ACCESSION NUMBER:		0001193125-17-236064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170726
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170726
DATE AS OF CHANGE:		20170726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		17982017

	BUSINESS ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d428552d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report: July&nbsp;26, 2017 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH
SYSTEMS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16133</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1245881</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1633 Broadway, Suite 22C, New York, New York 10019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) 489-2100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NONE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by checkmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2017, the Company issued a Letter to Stockholders in connection with the Definitive Schedule 14A filed with the SEC on the same date. A copy
of the Letter to Stockholders is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item&nbsp;8.01 by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following exhibit is filed herewith: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter to Stockholders of the Company, dated July&nbsp;26, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">DELCATH SYSTEMS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July&nbsp;26, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer K. Simpson, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jennifer K. Simpson, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter to Stockholders of the Company, dated July&nbsp;26, 2017.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d428552dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428552g35r30.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;26, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delcath Letter to Stockholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To My
Fellow Stockholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I write to <B>ask for your support for a reverse stock split</B> as outlined in the accompanying Schedule 14A. This is the only item
on the 14A and we ask you to vote <B><U>FOR</U></B> the Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To continue to fund our operations and support our clinical programs, we need the
ability to issue common shares, both to service the amortization of our Convertible Note and to explore alternative equity financing. However, <B>we are currently at the threshold of the Authorized Shares limit in our Certificate of
Incorporation</B>. Without a sufficient number of authorized shares, we are unable to access the $11.8 million of cash in the restricted account associated with the Convertible Notes issued last year, or to undertake any type of equity fund raise.
The proposed reverse split of our common shares will reduce the shares outstanding and provide us with the flexibility to raise equity capital and support our important clinical trials and our commercial efforts in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July, we issued two series of preferred stock (Series A Preferred Stock and Series B Preferred Stock) in transactions with holders of our Convertible Note.
The Series A shares were issued to address a short-term valuation issue for common shares delivered to the Note holders to close an installment period. Through the Series A Preferred Shares placement, we were able to value the open installment
shares such that the amount of debt remaining under the Convertible Note was reduced by $4.2 million. The Series B Preferred Shares, which are convertible to common shares at $0.153, allowed us to raise $2.0 million in unrestricted cash. This was
critical to our ongoing operations because we are unable to access cash in the restricted accounts related to the Convertible Note. There is $13.7 million in debt remaining under the Convertible Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effecting the reverse stock split will also allow Delcath to remain in compliance with NASDAQ exchange stock listing requirements, which provides liquidity
and other important benefits to the Company and its investors<B>. It is important to note that the floor price for the Convertible Note will adjust with the effected reverse stock split ratio to a minimum of $1.00</B>. We believe this should serve
to support the stock price following a split and reduce future potential dilution related to the Convertible Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For these reasons, we need your
support of our proposed reverse stock split in order for Delcath to move forward successfully, and on behalf of Delcath&#146;s management team and Board of Directors, I am seeking your support by voting <B><U>FOR</U></B> the reverse stock split so
we can continue to build Delcath into a leading interventional oncology company. All investors are encouraged to read our Definitive Schedule 14A in detail for full information regarding the proposed reverse stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We appreciate your support and look forward to reporting on our continued clinical and commercial progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428552g44r89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer K. Simpson, Ph.D., MSN, CRNP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1633
Broadway, Suite 22C, New York, NY 10019 | T: 212-489-2100 | F: 212-489-2102 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428552g35r30.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc.&nbsp;is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational
product&#151;Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) &#151;is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the fall of 2017. Melphalan/HDS has not been
approved by the&nbsp;U.S. Food&nbsp;&amp; Drug Administration&nbsp;(FDA) for sale in the U.S.&nbsp;In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Securities
Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause
actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to:&nbsp;the timing and results of the Company&#146;s&nbsp;clinical trials including without
limitation the OM and ICC clinical trial programs,&nbsp;timely enrollment and treatment of patients in the global Phase 3 OM clinical trial, IRB or ethics committee clearance of the&nbsp;Phase 3 OM and ICC Registration trial&nbsp;protocols
from&nbsp;participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual
Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any&nbsp;of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver
and filter melphalan in Europe including the key markets of Germany and the UK, the Company&#146;s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for
patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or
other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company&#146;s ability to successfully enter into strategic partnership and distribution
arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the
Company&#146;s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events
or circumstances after the date they are made. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1633 Broadway, Suite 22C, New York, NY 10019 | T: 212-489-2100 | F: 212-489-2102 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g428552g35r30.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428552g35r30.gif
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MUJ6MUN_W_^_O_\[.Y\[6[[W.YY2MQ@ Q<\[>YP I:QA">P
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MV45(0+01.($)5#"#PD9%!">X3"*$VH4X/N$*5^"6%GIV)R[T#0E5**\F.L
MAD7  8(@0?"0<#Q#>$!8@D# !03!7$(T*3I]2:#>,K"X_D<$8 =(O( -TI$
MYCV  ]Y%A :Z<*V7W$@+"/@ B,& RE1:(9"9B  '%@N )] G!1H;;L@(<0*^
M#D($*B   53P/1&,   H"%D'] 8" >#V$4@P4J8D<P#F$<!I@NP1'[6THQ[)
M50;[:>(F,( OC[G  ]]SFPCT9(#@":(!6&303*0K" ]45@9&?D0)"Z$";SG!
M>H)(@-X64:TR#D('4Y#" VP8@#I9(0N:T $;#Z"82@F >2T6A U^/(@&A)D
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M@!/T0  7,(  -O "##!  8I120)8,  5',$@Z1  !Y)P 0[ P $S\( 23M
M"7R' 1N 2@:6P $",($G&&@!-$20A 'H=0,B*$ -!K"!!A" ^%XY@0(&$(,(
M -\$'." $R2@@ XL7@5;J>TH!N\"$+P@ S!@0 PP\(+PRR &#'"  !AP @;,
M0 4G0 ,'H  Q '\4(  -\ *)9P,W< (DP0 %X &2=P,OD /0!0 <L ,+H (X
MH (P( $\,$ )T +)-G^"T .35P OT#')-P(@P $JT  <Y? #;7<#TF=YG0<$
M*A #(_ ""( #%A $)>@"(L !0G !C\8!,\ "0V *":  !K  #-  !^  #U
M!P !"7 5$]"%S76 "4 !%6 !%X !&5  &4  5N@ #;<!6$)?'C !&. !'R !
M7'$!^U!D#! "&%  %  J!>!C!4 6$0 !#E !)+!M4&@ &D  %)  ): !)H
M!I!<"P !#8 " C!M*: ""Q"((U  *U  %Y !*C  >T@ +*!R<B0  [!L?:5K
H$#(  ,:*MGB+N)B+NKB+O-B+OOB+P!B,PCB,Q%B,QGB,R/B+@0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g428552g44r89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428552g44r89.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)AGDCSN5\=\I@9]<T :A^)MD_B632K6PGN;=)XX#=QGY 6;83[C<0!CKSZ4
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< 4 % !0 4 % !0 8H * #% !B@ H * %H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
